

**TABLE 3**  
**Biogen Idec Inc.**  
**September 30, 2007**  
**Condensed Consolidated Statements of Income - Non-GAAP**  
**(in millions, except per share amounts)**  
**(unaudited)**

<b>EARNINGS PER SHARE</b>	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
GAAP earnings per share - Diluted	\$ 0.41	\$ 0.45	\$ 1.34	\$ 0.31
Adjustment to net income (as detailed below)	<u>0.17</u>	<u>0.15</u>	<u>0.54</u>	<u>1.40</u>
Non-GAAP earnings per share - Diluted	<u>\$ 0.58</u>	<u>\$ 0.60</u>	<u>\$ 1.88</u>	<u>\$ 1.71</u>
An itemized reconciliation between net income on a GAAP basis and net income on a non-GAAP basis is as follows:				
GAAP net income	\$ 119.4	\$ 156.6	\$ 437.0	\$ 109.0
Adjustments:				
COGS: Fair value step up of inventory acquired from former Biogen, Inc. and Fumapharm	-	2.9	-	7.8
COGS: Stock option expense	-	-	0.1	0.1
R&D: Restructuring	0.8	-	1.2	0.3
R&D: Stock option expense	3.5	5.2	9.4	16.4
SG&A: Merger related and purchase accounting costs	-	-	-	0.1
SG&A: Restructuring	-	-	0.6	1.6
SG&A: Stock option expense	5.9	7.7	17.3	24.3
Amortization of acquired intangible assets	65.7	60.0	186.6	207.0
In-process research and development related to consolidation of Cardiokine, and acquisitions of Syntonix, Conforma and Fumapharm	30.0	-	48.4	330.5
Gain on settlement of license agreement with Fumapharm	-	-	-	(34.2)
Gain on sale of long lived assets and impairments	-	0.2	-	(0.9)
Other income, net: Consolidation of Cardiokine and gain on sale of long lived assets	(38.0)	-	(38.0)	-
Income taxes: Income tax effect of reconciling items	(16.9)	(25.6)	(49.5)	(64.9)
Cumulative effect of accounting change from adoption of FAS123R, net of income tax	-	-	-	(3.8)
Non-GAAP net income	<u>\$ 170.4</u>	<u>\$ 207.0</u>	<u>\$ 613.1</u>	<u>\$ 593.3</u>

*Numbers may not foot due to rounding.*